<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>Alpha Tau Medical Ltd.（DRTS）的股价在周一的盘前交易中上涨超过 12%，达到 9.60 美元，此次上涨是由于其美国 Alpha DaRT 复发性胶质母细胞瘤试验 REGAIN 的中期结果令人鼓舞。</p>
<p>REGAIN 研究是一项前瞻性、开放标签、单臂干预研究，旨在评估 Alpha DaRT 在复发性胶质母细胞瘤潜在治疗中的可行性和安全性，这是一种最常见且最具侵袭性的脑癌。</p>
<p>Alpha DaRT（扩散α放射治疗）旨在将镭-224 直接输送到肿瘤中，以释放强烈的局部α辐射，精确靶向并摧毁实体癌细胞。</p>
<p>根据国家脑肿瘤协会的数据，胶质母细胞瘤是最复杂、最致命且对治疗抵抗力最强的癌症之一，估计平均生存率仅为 8 个月。</p>
<p>REGAIN 研究旨在招募 10 名脑癌患者，今天报告的中期结果来自首批接受治疗的三名患者。</p>
<p>根据试验结果，三名接受治疗的患者中有两名显示出完全反应，所有增强肿瘤病灶在多次治疗后 MRI 扫描中完全消失。</p>
<p>Alpha Tau 的首席医疗官 Robert Den 对研究结果评论道：“看到我们复发性胶质母细胞瘤方案的这些中期结果令人非常欣慰。在这种复发后中位生存期通常低于 12 个月的疾病中，令人鼓舞的方法屡次未能转化为成功结果，这种活性和耐受性的特征为我们推进试验至完全招募提供了强有力的依据。”</p>
<p>当我们在 2025 年 12 月 11 日提醒读者关注 DRTS 时，股价为 5 美元。该股票在 2026 年 5 月 8 日（周五）的收盘价为 8.51 美元，上涨 8.41%。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

DRTS

<p>Alpha Tau Medical Ltd.（DRTS）的股票在盘前交易中上涨超过 12%，达到 9.60 美元，此前其针对复发性胶质母细胞瘤的 REGAIN 试验发布了积极的中期结果。该研究旨在评估 Alpha DaRT 治疗的安全性和可行性，结果显示三名患者中有两名完全缓解，未见肿瘤病灶。首席医学官罗伯特·登（Robert Den）对结果表示乐观，强调了推进试验的潜力</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Shares of Alpha Tau Medical Ltd. (DRTS) are up over 12% at $9.60 in premarket trading on Monday, following encouraging interim results from its U.S. Alpha DaRT recurrent glioblastoma trial, dubbed REGAIN.</p>
<div class="lb-trans"><p>Alpha Tau Medical Ltd.（DRTS）的股价在周一的盘前交易中上涨超过 12%，达到 9.60 美元，此次上涨是由于其美国 Alpha DaRT 复发性胶质母细胞瘤试验 REGAIN 的中期结果令人鼓舞。</p>
</div><p>The REGAIN study is a prospective, open-label, single-arm interventional study designed to evaluate the feasibility and safety of Alpha DaRT for the potential treatment of recurrent glioblastoma, the most common and aggressive form of brain cancer.</p>
<div class="lb-trans"><p>REGAIN 研究是一项前瞻性、开放标签、单臂干预研究，旨在评估 Alpha DaRT 在复发性胶质母细胞瘤潜在治疗中的可行性和安全性，这是一种最常见且最具侵袭性的脑癌。</p>
</div><p>Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to deliver radium-224 directly into tumors to release strong, localized alpha radiation that precisely targets and destroys solid cancer cells.</p>
<div class="lb-trans"><p>Alpha DaRT（扩散α放射治疗）旨在将镭-224 直接输送到肿瘤中，以释放强烈的局部α辐射，精确靶向并摧毁实体癌细胞。</p>
</div><p>Glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months, according to the National Brain Tumor Society.</p>
<div class="lb-trans"><p>根据国家脑肿瘤协会的数据，胶质母细胞瘤是最复杂、最致命且对治疗抵抗力最强的癌症之一，估计平均生存率仅为 8 个月。</p>
</div><p>The REGAIN study is designed to enroll 10 brain cancer patients and the interim results reported today were from the first three treated patients.</p>
<div class="lb-trans"><p>REGAIN 研究旨在招募 10 名脑癌患者，今天报告的中期结果来自首批接受治疗的三名患者。</p>
</div><p>According to the trial results, two of the three treated patients showed a complete response, with total disappearance of all enhancing tumor lesions on multiple post-treatment MRI scans.</p>
<div class="lb-trans"><p>根据试验结果，三名接受治疗的患者中有两名显示出完全反应，所有增强肿瘤病灶在多次治疗后 MRI 扫描中完全消失。</p>
</div><p>Commenting on the study results, Robert Den, Chief Medical Officer of Alpha Tau, said, &#34;It is immensely gratifying to see these interim results of our recurrent glioblastoma protocol. In a disease where median survival after recurrence is typically under 12 months and where promising approaches have repeatedly failed to translate to successful outcomes, this profile of activity and tolerability gives us strong rationale to advance the trial toward full accrual.&#34;</p>
<div class="lb-trans"><p>Alpha Tau 的首席医疗官 Robert Den 对研究结果评论道：“看到我们复发性胶质母细胞瘤方案的这些中期结果令人非常欣慰。在这种复发后中位生存期通常低于 12 个月的疾病中，令人鼓舞的方法屡次未能转化为成功结果，这种活性和耐受性的特征为我们推进试验至完全招募提供了强有力的依据。”</p>
</div><p>When we alerted readers to DRTS on December 11, 2025, it was at $5. The stock closed Friday's (May 8, 2026) trading at $8.51, up 8.41%.</p>
<div class="lb-trans"><p>当我们在 2025 年 12 月 11 日提醒读者关注 DRTS 时，股价为 5 美元。该股票在 2026 年 5 月 8 日（周五）的收盘价为 8.51 美元，上涨 8.41%。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

Alpha Tau 在脑癌研究数据上重新获得了发展势头